
H Marijke Van Den Berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3618142/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	2.1	915
2	Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1935-1939.	3.8	530
3	Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4648-4654.	1.4	449
4	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	27.0	383
5	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	1.4	305
6	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	1.4	287
7	Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4693-4697.	1.4	220
8	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 2013, 122, 1129-1136.	1.4	200
9	Longâ€ŧerm outcome of individualized prophylactic treatment of children with severe haemophilia. British Journal of Haematology, 2001, 112, 561-565.	2.5	166
10	Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 1383-1390.	3.8	134
11	Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia, 2005, 11, 438-443.	2.1	125
12	Phenotypic heterogeneity in severe hemophilia. Journal of Thrombosis and Haemostasis, 2007, 5, 151-156.	3.8	106
13	Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia, 2004, 10, 565-571.	2.1	105
14	Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia, 2005, 11, 43-48.	2.1	91
15	Cysteine-mutations in von Willebrand factor associated with increased clearance. Journal of Thrombosis and Haemostasis, 2005, 3, 2228-2237.	3.8	80
16	Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. Journal of Thrombosis and Haemostasis, 2008, 6, 2048-2054.	3.8	74
17	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	1.4	71
18	Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia, 2014, 20, e280-6.	2.1	60

H Marijke Van Den Berg

#	Article	IF	CITATIONS
19	Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia, 2003, 9, 27-31.	2.1	44
20	Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 2002, 43, 528-532.	1.1	31
21	Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia, 2007, 13, 111-114.	2.1	27
22	Prophylaxis for Severe Hemophilia: Experience from Europe and the United States. Seminars in Thrombosis and Hemostasis, 2003, 29, 049-054.	2.7	25
23	Assessments of outcome in haemophilia – what is the added value of <scp>QoL</scp> tools?. Haemophilia, 2015, 21, 430-435.	2.1	25
24	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
25	Registries supporting new drug applications. Pharmacoepidemiology and Drug Safety, 2017, 26, 1451-1457.	1.9	23
26	Clinical prediction models for inhibitor development in severe hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 98-102.	3.8	18
27	Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia, 2015, 21, 227-233.	2.1	18
28	Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thrombosis and Haemostasis, 2016, 115, 729-737.	3.4	18
29	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	2.1	18
30	The growing number of hemophilia registries: Quantity vs. quality. Clinical Pharmacology and Therapeutics, 2015, 97, 492-501.	4.7	16
31	Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors. Haemophilia, 2014, 20, 76-79.	2.1	15
32	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	3.4	13
33	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	2.1	13
34	Different impact of factor VIII products on inhibitor development?. Thrombosis Journal, 2016, 14, 31.	2.1	10
35	Plasma products do not solve the inhibitor problem. Haemophilia, 2017, 23, 346-347.	2.1	9
36	Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia, 2016, 22, 9-13.	2.1	8

#	Article	IF	CITATIONS
37	Standardizing patient outcomes measurement to improve haemophilia care. Haemophilia, 2016, 22, 651-653.	2.1	7
38	ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study. Thrombosis and Haemostasis, 2020, 120, 1166-1172.	3.4	7
39	Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources. Haemophilia, 2018, 24, 420-428.	2.1	6
40	Assessment of Clotting Factor Concentrates—Pivotal Studies and Long-Term Requirements. Seminars in Thrombosis and Hemostasis, 2015, 41, 855-859.	2.7	5
41	Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia Blood, 2004, 104, 3086-3086.	1.4	5
42	Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?. Haemophilia, 2016, 22, 647-650.	2.1	4
43	Variability in Bleeding Pattern of Severe Hemophilia Blood, 2004, 104, 3094-3094.	1.4	4
44	Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registryâ€based study. Haemophilia, 2020, 26, 809-816.	2.1	2
45	Validation of the prediction model for inhibitor development in PUPs with severe haemophilia A. Haemophilia, 2016, 22, e116-e118.	2.1	1
46	From treatment to prevention of bleeds: what more evidence do we need?. Haemophilia, 2017, 23, 494-496.	2.1	1
47	Product choice and haemophilia treatment in the Netherlands. Haemophilia, 2001, 7, 96-98.	2.1	0
48	Improvement of patient education and information: development of a patient's information dossier. Haemophilia, 2001, 7, 397-400.	2.1	0
49	Reply to the letter of O'Mahoney et al Haemophilia, 2016, 22, e209-11.	2.1	0
50	International collaboration is needed to reduce the risk for inhibitors in <scp>PUP</scp> s with severe haemophilia A. Haemophilia, 2018, 24, e242-e243.	2.1	0